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Surgical Challenges of Chronic 




Chronic empyema has always been a clinical challenge for physicians. There is 
no standard procedure or treatment to deal with the situation, and multi-modality 
approach is often necessary. Surgical intervention plays a very crucial role in the 
treatment of chronic empyema. Since bronchopleural fistula is often seen in chronic 
empyema patients, therefore it should also be mentioned. In this chapter, the focus 
will be on the different treatment options, various surgical approaches, and the ratio-
nale behind every single modality. Certain specific entity will be included as well, such 
as tuberculosis infection, post lung resection empyema, and intrathoracic vacuum 
assisted closure system application. Even with the advancement of technology and 
techniques, chronic empyema management is still evolving, and we look forward to 
less traumatic ways of approach with better outcome in the future.
Keywords: Empyema, bronchopleural fistula, open window thoracostomy, VAC, 
Clagett procedure, thoracoplasty, muscle flap transposition
1. Introduction
Empyema is a common clinical problem to both pulmonary physicians and 
thoracic surgeons. It affected 65,000 patients annually in the US [1]. Thanks to the 
advent of antibiotics and continuous advancement of minimally invasive proce-
dures, most acute empyema patients can now receive tube thoracostomy and/or 
video-assisted thoracoscopic surgeries (VATS) to alleviate the infection with good 
recovery [2]. Empyema, also known to be pleural empyema or thoracic empyema, 
is defined as infection in the pleural cavity. The most common scenario is that the 
patient has a prior or ongoing pneumonia which the infection has extended to 
the lung surface, causing a series of inflammation and infection response on the 
visceral pleura and therefore parietal pleura. The products of the infection then 
accumulate in the pleural space resulting in empyema. Some patients would develop 
pleuritic pain which they easily mistake it as muscle strains or sprains, so they tend 
to overlook the real problem and lead to delay diagnosis. There are also a lot of other 
reasons that can eventually cause empyema, such as trauma, invasive procedures 
(including thoracic operation), liver abscess, spinal abscess, mediastinitis (because 
in the vicinity of an infection source) or being transmitted through hematog-
enous route.
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2. Stages of empyema
According to American Thoracic Society classification, empyema is divided 
into three stages (Table 1) [3, 4]. In the early stage of pleural cavity infection, 
some fibrin would develop in this avascular space along with some body fluid. It is 
often recognized as parapneumonic pleural effusion. At this exudative phase, most 
fluid in the pleural cavity can be drained by a chest tube. If the infectious process 
continues and the fluid accumulates, the fluid will become thicker with more fibrin 
deposition. This second stage is often characterized by loculated pleural effusion 
which makes it difficult to drain all effusion in different areas with a single chest 
tube. Patients with this true empyema stage often require surgical intervention to 
deloculate the effusion for complete drainage. Fibrinolytic agent is another option 
for non-surgical candidate. When the disease progresses, more and more fibrin 
pile up and the fluid becomes denser and denser. A thick peel will form to cover all 
contact surfaces, including lung, inner chest wall, diaphragm, and mediastinum. 
This final stage of empyema, organizing phase, will restrict lung expansion and 
hence reduce lung compliance. More aggressive treatment modalities should always 
be considered to avoid long-term lung function impairment.
3. Treatment principles
Since empyema equals to infected pleural cavity, the primary goal is to treat the 
infection. There are a few recognized treatment principles to such disease. First, 
sterilization of the pleural space. Second, adequate drainage. Third, optimizing 
lung expansion and reducing potential pleural space. These principles will be 
explained in detail below.
3.1 Sterilization of the pleural space
Just like treating other infectious disease, removal of pus or necrotic tissue 
and antibiotics therapy are the two key components to successful treatment. In 
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empyema, sterilization targets not only the pleural space but also the original 
infection source, such as pneumonia or liver abscess. To select effective antibiot-
ics, obtaining cultures are important so that adjustment can be made according 
to susceptibility test after empirical antibiotics. Other effective ways to lower the 
pathogen colonization in the pleural cavity are removal of the infectious debri and 
irrigation. These procedures, debridement and irrigation, are often carried out 
during the surgery, either through VATS or thoracotomy. Although some doctors 
believe irrigation may result in unstable hemodynamics as capillary permeability 
increases due to transient bacteremia, the author thinks it is reasonable to do so as 
it is easier and faster to achieve sterilization. If the patient’s blood pressure drops 
during the surgery, it is suggested to irrigate the pleural cavity with some diluted 
epinephrine with cautious monitoring. Since the patient’s capillary permeability 
may increase, it is possible that the patient would develop tachycardia and hyper-
tension if the medication is well-absorbed by the pleura.
3.2 Adequate drainage
Unlike airway, pleural cavity is a closed space. The fluid should be drained 
adequately to avoid further or repeated infection. A chest tube is sufficient for 
simple parapneumonic pleural effusion (stage I empyema) while complicated 
pleural effusion (stage II empyema) or organizing empyema (stage III empyema) 
often requires surgical intervention and a chest tube(s) after the surgery for 
adequate drainage.
3.3 Optimizing lung expansion and reducing potential pleural space
When the empyema reaches to its final stage --- organizing stage, the lung would 
become completely trapped and therefore poorly expanded. This not only leads to 
restrictive lung (impaired lung function), but also leaves a potential dead space in 
the pleural cavity. This space would possibly result in repeated infection. Therefore, 
the initial treatment goal of empyema should also include best pleural apposition 
to prevent chronicity. To achieve this, remove “peels” from the lung and other 
pleural surfaces. This surgical procedure is known as “Decortication.” As long as it is 
feasible, removing all debri and resuming patients’ optimal pulmonary function are 
always recommended. However, there could be exceptions that the lung fails to fill 
the pleural cavity. If this is the case, other measures should be taken to reduce the 
potential pleural space.
From a thoracic surgeon’s point of view towards managing empyema, it is always 
“the earlier the easier.” In an acute setting of empyema (stage I or II), most patients 
can be cured by tube thoracostomy or VATS [2]. This further emphasizes the fact 
that early diagnosis and early aggressive treatment to prevent chronicity are crucial. 
In addition, the choice of first intervention is important as well. According to the 
literature, failure of the first attempted procedure was an independent predictor of 
death [5]. As a result, operation is the most successful initial procedure in this study. 
More and more studies demonstrated good outcomes of early surgical intervention 
treating complex empyema [5, 6]. Furthermore, VATS decortication is found to 
be superior to open surgery in the management of primary empyema [7]. In the 
author’s hospital, empyema is a surgical disease. Once the diagnosis is made, almost 
all patients need surgical consult for further treatment planning. All surgeons 
tacitly agree that VATS is the gold standard procedure to treat acute empyema in the 
author’s institution.
There are still certain patients who will eventually continue to have the infection 
and enter to a chronic phase. Several causes of chronic empyema include delayed 
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diagnosis, retained hematoma in the pleural cavity, bronchopleural fistula with 
continuous airway secretion spillage, a large potential pleural space (e.g. post lung 
resectional empyema) which is prone to have repeated infection, and the patient is 
too ill to receive definite treatment at the initial acute phase. Among all the causes, 
the author thinks that retained hematoma in the pleural cavity is the most prevent-
able cause of chronic empyema. Blood clots are perfect culture medium for bacteria, 
so it is important to avoid too much oozing when one performs VATS debridement 
and decortication on empyema patients, especially those who have liver cirrhosis, 
end stage renal disease, or other bleeding tendency. Adequate hemostasis and 
diluted epinephrine irrigation are helpful to prevent retained hematoma. If retained 
hematoma still happens, at least it is detectable from the drainage fluid. The drained 
fluid would be bloody initially then turned to dark brown and remained in this 
color without turning to light yellow. As one recognizes the sign of retained hema-
toma in the pleural cavity, it is often required to do another operation to remove all 
the blood clots to prevent chronic empyema.
4. Treatment options
In this section, the focus will be solely on the treatment options of chronic 
empyema and to which treatment principles that each option fits in.
When dealing with empyema, following the above mentioned three treatment 
principles is the key to success. Although the principles are the same in different 
stages, treatment strategies may vary, especially in the chronic stage. Treating 
chronic empyema is more complicated, more unpredictable, and therefore more 
challenging. It may require staged operations, different surgical approaches, 
and there is no standardized option. Before establishing treatment plan for 
chronic empyema patients, comprehensive understanding between each option is 
necessary.
4.1 Optimizing lung expansion by decortication
Decortication can be done either through VATS or thoracotomy. It is basically 
surgeon’s preference. During the same surgery, debridement is also done so that 
non-viable tissue and debri are removed to achieve “cleaning” in the pleural cavity. 
In stage III empyema, the lung is always restricted by thickened “cortex,” so freeing 
the lung by decortication can optimize lung expansion and reduce the potential 
pleural space. Choosing proper surgical instruments accelerates the procedure. In 
the author’s experience, Roberts artery forceps or long Kelly forceps are best tools to 
separate the lung from the overlying “cortex.” This separation process can be done 
sometimes with the operated lung ventilating so that the correct pleural plane is 
evident. If pleural apposition still cannot be achieved after decortication, make sure 
to check the lung surface again. There may be some remnant peel from the multi-
layered peel that restricts lung expansion. Sometimes the peel is extremely thick 
and firm. Using a scalpel cautiously to slit through the peel will aid in removal.
*Fitting in the treatment principles sterilization of the pleural cavity and reducing 
potential pleural space by optimizing lung expansion.
4.2 Optimizing lung expansion by other means
To optimize lung expansion, there are several other ways, but none are as effective 
as decortication.
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4.2.1 Positive airway pressure
Some of these patients are ventilator dependent while others are not. If they 
still require ventilator support, it is acceptable to increase positive end-expiratory 
pressure (PEEP) a little, by 1 or 2 cmH2O, to further expand the lung. If patients 
can be weaned off from ventilator successfully after the operation, a strategical 
management option is to delay extubation time by 0.5 to 1 day. This may also allow 
the lung to further expand.
*Fitting in the treatment principle reducing potential pleural space by optimizing 
lung expansion.
4.2.2 Negative pleural pressure
Positive airway pressure expands the lung from internal while negative pleural 
pressure provides a tractive force externally. A suction pressure of −20 cmH2O is 
usually recommended with a traditional chest drainage system. Other modality that 
can create negative pressure in the pleural cavity is Vacuum-assisted closure (VAC) 
therapy. (see 4.4).
*Fitting in the treatment principles drainage and reducing potential pleural 
space by optimizing lung expansion.
4.3 Open window thoracostomy (OWT)
4.3.1 History of OWT
OWT was first described by Robinson in 1916 and then revised by Leo Eloesser 
in 1935 which was also called Eloesser flap thoracostomy window [8]. However, 
the most adopted OWT is modified by Symbas and coworkers in 1971 as modified 
Eloesser flap [9].
4.3.2 Rationale, advantage, and disadvantage of OWT
This procedure, an open drainage method, is often saved as the last resort to 
treat chronic empyema, especially when the pleural infection is difficult to be man-
aged by debridement and decortication. It is also a treatment option for critically 
ill patients who are too weak to receive decortication. As the name presents itself, 
OWT is to create a window through the patient’s chest so serial dressing changes 
are feasible to clean the infected pleural cavity and therefore alleviate the septic 
condition. The advantage of OWT is that it is proved to be safe and effective [10]. 
On the other hand, it affects the patient’s appearance and may cause chronic pain 
after chest wall resection. Some of the patients will need another surgery to close up 
the wound.
*Fitting in the treatment principles sterilization of the pleural cavity and 
drainage.
4.3.3 Surgical techniques and special considerations of OWT
The most common use of OWT is modified Eloesser flap [11]. The window 
is usually created at the basal part of the hemithorax where most of the infected 
material accumulates (Figure 1). After confirming the chest CT image, an 
inverted U-shaped incision is made at this area. Electrocautery is used for dis-
section till the rib cage. In order to create a sufficient window, two or three 
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ribs need to be resected. Then, the tongue-shaped muscular-cutaneous flap is 
folded inward and sutured to the diaphragm (Figure 2). The remaining wound 
edge is sutured to the pleura so that the window can be maintained for a period 
of time without spontaneous closure. It is also imperative that the window is 
large enough for the convenience of frequent wet packings. Another key point 
that must be mentioned is the timing of OWT creation. From the Massera et al. 
study [12], immediate OWT requires lesser time for the resolution of empyema 
comparing to the delayed OWT after prolonged chest tube drainage. As a result, 
the median OWT closure time (between performing and closing of OWT) of 
immediate OWT was 8 months shorter than that of delayed OWT. The timing of 
attempted closure should be carefully decided by the surgeon after a thorough 
evaluation of the empyema patient’s condition. This includes free from recurrent 
disease, good recovery of the pleural cavity with coverage by healthy granulation 
tissue, the patient’s general condition, and to a lesser degree by the normaliza-
tion of inflammatory parameters [12, 13]. Methods of OWT closure please see 
4.6.2 below.
Figure 1. 
OWT. An OWT on the patient’s left-side chest wall.
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4.4 Vacuum-assisted closure (VAC) therapy
4.4.1 History of VAC therapy
VAC is a negative pressure wound therapy that is widely used in acute and 
extended open wounds. The first case report of intrathoracic VAC therapy was 
published in 2006 [14]. Varker et al. managed a postlobectomy empyema patient 
with VAC device successfully after open debridement of the empyema cavity. In the 
next following decade, with the popularity of VAC therapy, it was proved that it is 
safe and efficient to fight against all kinds of intrathoracic infections [13, 15–17].
4.4.2 Rationale, advantage, and disadvantage of VAC therapy
VAC device is able to create a negative pressure wound environment that 
promotes wound healing by reducing edema, promoting granulation tissue forma-
tion and perfusion, and removing exudate and infectious material. As to treating 
chronic empyema, it is a useful tool to apply on an open wound such as an OWT 
after debridement of the pleural cavity (Figure 3). In the setting of intrathoracic 
VAC usage, it may reduce the duration and frequency of dressing changes neces-
sary for spontaneous chest closure or a space filling procedure, reducing patient’s 
Figure 2. 
Coronal view of the Eloesser flap window. Demonstrating the supposition of the skin surface of the inferiorly 
based soft tissue flap to the diaphragmatic surface. (Adapted from Denlinger [11].)
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Figure 4. 
Mini-VAC procedure. VAC therapy is applied through the ALEXIS wound retractor which creates a similar 
window effect without resecting the ribs.
discomfort, and resolving the infectious process faster [18]. When compared 
with conventional management of OWT, VAC therapy accelerates wound heal-
ing and helps re-expansion of residual lung parenchyma in patients with OWT 
[19]. In selected patients, applying Mini-VAC procedure can even avoid OWT by 
insertion of the ALEXIS (Applied Medical, Rancho Santa Margarita, CA, USA) 
wound retractor to create a similar window effect without resecting the ribs which 
preserves the chest wall integrity and avoids the consequences that OWT can 
cause (Figure 4) [20]. However, the biggest disadvantage of this device is that it is 
not suitable for everyone. VAC device should be used cautiously or be avoided on 
patients with bleeding tendency, presence of malignancy, or unstable hemodynam-
ics. Because VAC creates a negative pressure environment, it may lead to continuous 
bleeding, promote cancer growth, or deteriorate hypotension. The reason why 
Figure 3. 
Intrathoracic VAC therapy. VAC therapy is applied through the patient’s OWT.
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hypotension may develop is probably due to the negative pressure effect intratho-
racically causing decreased cardiac output. Thus, intrathoracic application in older 
patients must be monitored closely and should be avoided on patients with poor 
cardiac function.
*Fitting in the treatment principles drainage and reducing potential pleural 
space by optimizing lung expansion.
4.4.3 Surgical techniques and special considerations of VAC therapy
VAC therapy is designed to be applied on open wounds. To treat chronic 
empyema with VAC, an open chest wound or an OWT must be created during the 
surgical intervention. Some authors advocate leaving the thoracotomy wound open 
directly after the operation [13, 14] while others create an OWT to make dressing 
changes easier [17–19]. It is reasonable to decide on an individual basis depending 
on the size and depth of the residual pleural space. A large and deep residual pleural 
space is preferred for OWT. The advantage of OWT is that the chest will stay open 
for a longer period because of the inverted skin flap compared to just leaving the 
thoracotomy wound open. OWT would avoid the skin from healing before com-
plete eradication of the infected pleural cavity. It is contraindicated to apply VAC 
on a dirty wound with necrotic tissue that has yet to be debrided. After adequate 
debridement in the pleural cavity, VAC sponges (GranuFoam) are inserted in the 
residual pleural space to fill the entire cavity. Placing the sponges directly in contact 
with exposed blood vessels, anastomotic sites, organs, or nerves are prohibited, 
except for the lungs. According to the literature [13, 21] and the author’s personal 
experiences, VAC dressing can be safely applied directly on the visceral pleura or 
lung parenchyma without any complications. The negative pressure can be set at 
-50 mmHg from the start, and gradually increased to -125 mmHg if the patient does 
not have any discomfort. The dressing change should be done at least twice a week, 
and it can be performed at the bedside. During the VAC therapy period, the skin 
covered by the dressing should be well protected to prevent skin maceration prob-
lems. If negative pressure fails to be maintained due to significant air leak caused by 
bronchopleural fistula (BPF), combining a one-way valve may solve this issue [21].
When dealing with postpneumonectomy empyema (PPE), VAC therapy should 
be used carefully, especially for patients who develop the complication shortly after 
the initial surgery. This is because negative pressure would shift the mediastinum 
which may cause heart or great vessels herniation leading to obstructive shock or 
even cardiac arrest. On the contrary, if PPE is developed at a later stage, such events 
will not happen as the mediastinal shift has already completed and the patient’s 
body has compensated it well.
4.5 Empyema tube --- rationale, advantage, and disadvantage
There are two scenarios where chronic empyema patients would need an empy-
ema tube for long-term drainage. One is that the patient is too unstable and fragile 
to receive general anesthesia and adequate surgical intervention. To alleviate the 
septic condition, empyema tube (tube thoracostomy) can be placed to decrease the 
burden of infection until definite treatment can be initiated. Another scenario is 
that the chronic empyema is somehow localized in a small area without systemic 
infection. It is either a tube thoracostomy left after previous surgical intervention or 
a new chest tube inserted into this localized area for drainage if the patient is not a 
surgical candidate.
In the author’s opinion, this treatment option is only reserved for those who are 
not able to receive other definite treatment because of the low success rate, and not 
Pleura - A Surgical Perspective
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all infected materials can be drained adequately. However, if adequate drainage can 
be achieved, the tube may be slowly retracted over a period of weeks to months 
while the infected space heals behind it [3].
*Fitting in the treatment principle drainage.
4.6 Filling the potential pleural space with different measures
4.6.1 Clagett procedure
4.6.1.1 History, rationale, advantage, and disadvantage of Clagett procedure
Clagett procedure was first described by Clagett and Geraci in 1963 [22]. It is a 
method that obliterate the pleural cavity with antibiotic solution. As a precondition 
of the procedure, there must be no BPF and the pleural cavity should be sterilized 
by debridement and irrigation. In other words, if the patient has BPF and primary 
repair is impossible, Clagett procedure is not suitable for the patient. Nonetheless, 
this procedure has a good overall success rate in selected patients (no BPF at the 
time of the procedure), range from 81–100% [12, 23–25]. Those who fail from the 
procedure are mainly due to persistent or recurrent BPF.
*Fitting in the treatment principle reducing potential pleural space.
4.6.1.2 Surgical techniques and special considerations of Clagett procedure
After confirming that there is no active BPF in the pleural cavity or it is firmly 
closed, antibiotic fluid can be instilled to fill the remaining pleural cavity after it 
is fully cleansed. DAB solution (gentamicin 80 mg/L, neomycin 500 mg/L, and 
polymyxin B 100 mg/L) is one of the antibiotic solution choices [23]. The combina-
tion of the fluid can be chosen according to the microbiological findings [26].
4.6.2 Tissue flap transposition
4.6.2.1 Rationale, advantage, and disadvantage of tissue flap transposition
Tissue flap transposition technique is frequently used in chronic empyema 
patients for the purpose of either closure of the BPF or OWT, and/or obliteration of 
the residual pleural space. It can also be used for the prophylactic reinforcement of 
a bronchial stump after major lung resection to avoid BPF formation. Because the 
flap tissue is full of mesenchymal cells, it can promote granulation tissue growing 
under good circulation and secure the bronchial stump as a backup layer. A bulky 
muscle flap is extremely helpful to reduce the residual pleural space while a smaller 
residual space only requires a smaller tissue flap. However, not every patient is 
medically fit for long-hour flap surgery especially the critically ill. A successful 
flap reconstructive surgery is determined by a well-perfused flap which is highly 
dependent on patients’ stable hemodynamics.
*Fitting in the treatment principle reducing potential pleural space.
4.6.2.2 Surgical techniques and special considerations of tissue flap transposition
Tissue flaps commonly used in chronic empyema are latissimus dorsi (LD) 
muscle flap (Figure 5), serratus anterior (SA) muscle flap, pectoralis major (PM) 
muscle flap, intercostal muscle flap, pedicled omental flap, and other free flaps. LD 
is the largest muscle among all chest wall muscles. Therefore, it is an ideal option 
for pleural cavity obliteration. However, if the patient has received a standard 
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posterolateral thoracotomy previously, this muscle may have been compromised 
and hence not suitable. PM flap is another good alternative for it is the second 
largest chest wall muscles. Because of its anatomy and orientation, PM flap is 
particularly useful to obliterate the apical residual pleural space [3, 27]. Although 
SA flap and intercostal muscle flap are relatively small compared to LD and PM 
flaps, they can be sufficient to help accelerate BPF healing as long as the pedicle 
is healthy. Omental flap is another option if no chest wall muscle is available [28]. 
However, entering the peritoneal cavity may potentially spread the infection and 
complicate the situation. Sometimes the remaining pleural space is too big that only 
by combining two flaps will fill the space [27]. Free flap may also be considered in 
highly selected patients.
4.6.3 Thoracoplasty
4.6.3.1 History, rationale, advantage, and disadvantage of thoracoplasty
Thoracoplasty has a long history in the field of thoracic surgery. It was first 
described by Estlander in the late 19th century when tuberculosis was a trouble-
some pandemic without medical cure [29]. The original concept of this surgery is 
to collapse the chest wall to minimize the cavitary pleural space caused by myco-
bacterium. To achieve this goal, multiple ribs are resected resulting in loss of rigid 
chest wall configuration and therefore obliteration of the infected pleural space. 
Although it is an effective way to fill the potential pleural space, this procedure can 
cause significant morbidity, including chronic pain, chest wall deformity, thoracic 
spine scoliosis, limited ipsilateral shoulder range of motion, and finally resulting in 
poor quality of life.
*Fitting in the treatment principle reducing potential pleural space.
4.6.3.2 Surgical techniques and special considerations of thoracoplasty
Thoracoplasty can be classified into three types, full, extended, and tailored 
thoracoplasty. Full thoracoplasty is defined as removing first 11 ribs to collapse 
the whole hemithorax. Extended thoracoplasty, on the other hand, is removing 7 
Figure 5. 
LD muscle flap. Harvest of the LD muscle flap to reinforce the PPE BPF closure.
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to 9 ribs while tailored thoracoplasty is removing fewer than 5 ribs at certain area 
[30]. Resection of 7 ribs can lead to approximately 50% reduction of the pleural 
space, and resection of 5 ribs results in 25% reduction (Figure 6) [31]. The key to 
a successful thoracoplasty is complete resection of the targeted ribs which means 
from the transverse process of the thoracic spine posteriorly to the costosternal joint 
anteriorly. In the modern era, this procedure is seldom conducted alone. Combining 
with muscle flap transposition is an effective alternative so that chest wall deformity 
can be less significant [32, 33].
Managing chronic empyema is art. There is no standardized option. Knowing 
the different measures in depth and applying each principle with these measures 
will certainly increase the success rate of treatment. Making a customized treat-
ment plan according to the patient’s physical condition, complications, and special 
requirements cannot be emphasized enough. There are special circumstances which 
will be introduced below for better understanding of how to put the different treat-
ment options in use.
5. Special circumstances
5.1 Post-resectional empyema
The main issue contributed by post-resectional empyema is that the residual 
pleural space is often large. The treatment strategy therefore should be emphasized 
on how to fill the space. If post-lobectomy empyema occurs in a delayed setting, the 
size of the residual pleural space would not be a concern because the pleural cavity 
should have been remodeled by diaphragm elevation, mediastinum shifting, and 
narrowing of the intercostal space over time. However, if post-resectional empy-
ema happens in an acute phase when the remodeling has not been completed yet, 
different filling procedures should always be considered. For instance, if a patient 
who is medically fit for surgery develops a post-lobectomy empyema in a delayed 
phase, VATS or thoracotomy debridement and decortication are usually amenable to 
solving the problem.
Post-pneumonectomy empyema (PPE) is notorious for its high morbidity and 
mortality rate [12]. It is a challenging situation clinically, especially when BPF is 
present (Figure 7). According to the literature [12, 25, 30], approximately 65 to 
84% PPE patients have BPF. Closure of the BPF is imperative or else spillage from 
Figure 6. 
Thoracoplasty. Complete resection of the 4 right upper ribs. (Adapted from Lewis and Wolfe [31].)
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the infected cavity into the airway can cause pneumonia or even acute respiratory 
distress syndrome (ARDS). On the other hand, the secretion from the airway would 
also leak into the pleural space continuously and contaminate the cavity. After 
closing the BPF, as per treatment of other empyema, sterilization of the cavity with 
debridement, irrigation, parenteral antibiotics, and adequate drainage, the most 
important is effective obliteration of the remaining pleural space. Since the BPF is 
often failed by primary suture alone, covering the stump with pedicled muscle flap 
ensures secondary healing as well and obliteration the pleural space at the same 
time. For example, if a debilitated patient suffers from severe sepsis caused by late 
onset right-sided PPE with BPF, it is reasonable to lay out a staged surgical plan. 
First, do a tube thoracostomy and forbid the patient to lie in a left decubitus posi-
tion to protect the contralateral lung. This first stage is for drainage and lung protec-
tion. Second, perform simple debridement, OWT, and primary BPF repair added 
on a buttressed intercostal muscle flap. Instead of frequent dressing changes after 
OWT, VAC therapy can be initiated under the circumstance without any contraindi-
cation. VAC dressings can be changed at least twice a week. After a period of aggres-
sive treatment plus appropriate nutritional support, successful BPF closure, a clean 
pleural cavity covered with healthy granulation tissue, and improved physical status 
of the patient can be expected. The second stage is for sterilization of the pleural 
space and open drainage. The third stage is purely for filling. Choose an appropriate 
procedure, such as Clagett procedure, to obliterate the pleural cavity.
5.2 Bronchopleural fistula (BPF)
As mentioned in the last paragraph, BPF connects the bronchus to the pleural 
cavity leading to infection burden and possible respiratory distress. Life threatening 
events, such as ARDS or septic shock, must be managed as top priority. Successful 
closure of the BPF may prevent those critical situations from happening. As long 
as the patient’s physical condition is suitable for intervention, attempts to close the 
BPF should be carried out as early as possible.
There are several ways to manage BPF, either bronchoscopically or surgically. 
Treatment choices mainly depend on patients’ clinical status, duration before 
the development of BPF, and number and size of the BPF [30]. An algorithm for 
treatment of BPF at the European Oncologic Institute [34] (Figure 8) was created 
according to these principles. If the BPF occurs in an early setting (<14 days after 
surgery), surgical repair of the bronchial stump is always encouraged. In a delayed 
setting (>14 days after surgery), bronchoscopic application with sealants, fibrin 
glue, silver nitrate, coils, endobronchial stents, Endobronchial Watanabe Spigot, or 
atrial septal defect occluder device [35–38] can be used for small BPF size <8 mm 
or for patients who are physically unfit for surgery. As for BPF size >8 mm, patients 
Figure 7. 
PPE with BPFs. (A) from the thoracoscopic view of the BPFs (B) from the bronchoscopic view of the BPFs.
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who are fit for surgery, patients who had failure from other treatment strategies, 
surgical intervention is unavoidable. In addition to primary closure of the bron-
chial stump, muscle flap transposition to cover the sutured stump provides a good 
environment for secondary healing which may increase the success rate of closure. 
If the BPF is deemed to be closed during the operation, Clagett procedure may be 
considered after thorough cleansing of the infected pleural cavity. Since continu-
ous spillage from the BPF may occur, therefore OWT is often a treatment option to 
enable frequent dressing changes to eliminate the infection.
5.3 Malignant pleural empyema
At times, malignant pleural effusion can be infected either through hematog-
enous or direct inoculation by invasive procedures. The treatment principles are 
essentially the same. Sterilization of the pleural cavity and adequate drainage are 
not difficult to achieve. Since the pleura tumor cells cannot be eradicated immedi-
ately by surgical procedures or medical treatment, it is almost impossible to fully 
expand the lung via decortication and therefore a possible residual pleural space 
which can cause repeated infection. Under this circumstance, a thorough decortica-
tion is not practical because tumor cells are prone to bleed and cause the underneath 
lung tissue to be more fragile. Too much “peeling” will lead to excessive bleeding 
resulting in hematoma retention and causing the lung to tear. To weigh the benefits 
and risks of surgical intervention is crucial since the patient’s life expectancy may 
Figure 8. 
Management of PPE BPF: EOI algorithm. (Adapted from Mazzella et al. [34].)
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be limited. From the author’s personal experience, debridement, irrigation, and 
limited decortication followed by a tube thoracostomy are sufficient to treat the 
infected pleural cavity.
5.4 Tuberculous empyema
Although some surgical measures for chronic empyema originated from treating 
tuberculous (TB) empyema [8, 29], such as Eloesser flap thoracostomy window and 
thoracoplasty, these intensive procedures are now rarely used to treat TB empyema. 
It is not that TB empyema patients do not need invasive procedures, but it is that 
most of these patients can be managed by tube thoracostomy or VATS debridement 
with decortication. When it comes to uncontrolled TB empyema with initial treat-
ment attempt failure, more aggressive modalities should be considered which are 
the same as treating other bacterial chronic empyema.
5.5 Application of double lumen endotracheal tube
Double lumen endotracheal tube intubation is frequently seen in thoracic 
surgery for lung isolation. It can be an adjunct to help with BPF treatment after 
pneumonectomy if the patient still requires ventilator support or to protect the 
remaining lung from fistular spillage. Application of this device would help ven-
tilate the remaining side of the lung and leave the fistular side of the hemithorax 
unventilated to accelerate fistular healing. However, the diameter of the double 
lumen tube is certainly greater than the single lumen tube which would make the 
patient feel uncomfortable if not sedated. Another frequently encountered issue 
is that the left-sided tube tip would slide outward easily, and this malposition 
may cause failure of lung isolation. Although the whole diameter of the double 
lumen is greater than the single lumen tube, each individual double lumen tube 
diameter is smaller. This would make it difficult to clean the airway by suction 
as the suction tip may not always reach to the proper depth. As a result, airway 
hygiene may become a serious issue if the tube is placed in the bronchus for a 
long time.
6. Future directions
With the development of modern medicine and minimally invasive technology, 
the role of both bronchoscopic and thoracoscopic (VATS) procedures have become 
increasingly important replacing some of the traditional surgeries in treating 
chronic empyema. More studies should focus on solving existing issues like, Mini-
VAC replacing OWT completely, customized device to help repairing BPF, and 
3D bioprinting assisting BPF closure. The author believes that chronic empyema 
management is still evolving, and look forward to less traumatic ways of approach 
with better outcome in the future.
7. Conclusions
Treating chronic empyema and BPF are certainly clinical challenges that tho-
racic surgeons would encounter from time to time. It is necessary to thoroughly 
comprehend each treatment option and some management key points of different 
situations. With the development of modern technology, more treatment modalities 
can be anticipated.
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